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Background: While several observational studies suggested a lower postoperative mortality af-
ter minimal invasive endovascular aneurysm repair (EVAR) in patients with a ruptured abdom-
inal aortic aneurysm (RAAA) compared to conventional open surgical repair (OSR), landmark
randomized controlled trials have not been able to prove the superiority of EVAR over OSR.
Randomized controlled trials contain a selected, homogeneous population, influencing external
validity. Observational studies are biased and adjustment of confounders can be incomplete.
Instrumental variable (IV) analysis (pseudorandomization) may help to answer the question if
patients with an RAAA have lower postoperative mortality when undergoing EVAR compared
to OSR.
Methods: This is an observational study including all patients with an RAAA, registered in
the Dutch Surgical Aneurysm Audit between 2013 and 2017. The risk difference (RD) in
postoperative mortality (30 days/in-hospital) between patients undergoing EVAR and OSR
was estimated, in which adjustment for confounding was performed in 3 ways: linear model
adjusted for observed confounders, propensity score model (multivariable logistic regression
analysis), and IV analysis (two-stage least square regression), adjusting for observed and un-
observed confounders, with the variation in percentage of EVAR per hospital as the IV
instrument.
Results: 2419 patients with an RAAA (1489 OSR and 930 EVAR) were included. Unadjusted
postoperative mortality was 34.9% after OSR and 22.6% after EVAR (RD 12.3%, 95% CI
8.5e16%). The RD adjusted for observed confounders using linear regression analysis and pro-
pensity score analysis was, respectively, 12.3% (95% CI 9.6e16.7%) and 13.2% (95%CI 9.3e
17.1%) in favor of EVAR. Using IV analysis, adjusting for observed and unobserved con-
founders, RD was 8.9% (95% CI -1.1e18.9%) in favor of EVAR.
Conflicts of interest: The authors declare that they have no conflicts of
interest.
Funding: This research received no specific funding.
Reprints: Reprints will not be available from the authors.
1Department of Surgery, Leiden University Medical Center, Leiden,
The Netherlands.
2Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
3Department of Surgery, OLVG, Amsterdam, The Netherlands.
4Department of Clinical Epidemiology, OLVG, Amsterdam, The
Netherlands.
5Department of Clinical Epidemiology, Leiden University Medical
Center, Leiden, The Netherlands.
6Department of Medical Statistics and Bioinformatics, Leiden Uni-
versity Medical Center, Leiden, The Netherlands.
Correspondence to: Eleonora G. Karthaus, Department of Surgery
(Zone K6-R), Leiden University Medical Center, Albinusdreef 2, 2333
ZA Leiden, The Netherlands; E-mails: e.g.karthaus@gmail.com or
e.g.karthaus@lumc.nl
Ann Vasc Surg 2020; 69: 332–344
https://doi.org/10.1016/j.avsg.2020.06.015
 2021 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
Manuscript received: April 17, 2020; manuscript accepted: June 1,
2020; published online: 15 June 2020
332
Conclusions: Adjusting for observed confounders, patients with an RAAA undergoing EVAR
had a significant better survival than OSR in a consecutive large cohort. Adjustment for unob-
served confounders resulted in a clinical relevant RD. An ‘‘EVAR preference strategy’’ in patients
with an RAAA could result in lower postoperative mortality.
INTRODUCTION
In the elective treatment of abdominal aortic aneu-
rysms, minimal invasive endovascular aneurysm
repair (EVAR) has proven to be superior to conven-
tional open surgical repair (OSR) in the short-term/
midterm, with a lower postoperative mortality and
morbidity.1 Several randomized controlled trials,
however, failed to establish superiority of EVAR in
patients with a life-threatening ruptured abdominal
aortic aneurysm (RAAA), and no significant differ-
ences in immediate postoperative survival were
found.2e5 A drawback of these trials is that they
might contain only a selected population of patients
with an RAAA, which hampers the external validity
(generalizability) of the results.6 In addition,
randomization methods were different between
these trials and some were underpowered, affecting
the internal validity.6 Large observational studies,
adjusting for known confounders, suggested a lower
postoperative mortality in patients with an RAAA
treated with EVAR.7e9 However, observational
studies suffer from indication bias by important
prognostic baseline differences between patients
and the adjustment of confounders can be incom-
plete as clinical and social interactions in the
diagnostic-treatment pathway are often not
measured.10 For example, anatomic characteristics
of the aneurysm or the surgeon’s preference for
one or the other surgical procedure may influence
the choice of treatment in patients with an RAAA.
Using large databases with consecutive patients
and different treatment preferences of hospitals,
treatments, as applied in daily practice, can be
compared with pseudorandomization techniques.
Instrumental variable (IV) analysis is such a tech-
nique, as it is developed to control the unobserved
and/or unmeasured bias between different treat-
ment groups and tries to find a randomized experi-
ment embedded in an observational study, to
subsequently estimate the difference in the treat-
ment effect.11
The aim of this study was to investigate if patients
with an RAAA registered in the nationwide and
compulsory Dutch Surgical Aneurysm Audit
(DSAA) have a better postoperative survival when
treated with EVAR than with OSR, correcting for
observed confounders with standard statistical
methods and unobserved confounders with IV anal-
ysis (pseudorandomization). Second, the postopera-
tivemortality between hospitals with a high and low
preference for EVAR was compared.
METHODS
Study Design
This is a prospective observational study, which ex-
amines if patients with an RAAA have a lower post-
operative mortality after EVAR than OSR, adjusting
for observed and unobserved confounders.
Data Source, Participants, and Setting
The data set was retrieved from the Dutch Surgical
Aneurysm Audit (DSAA). This nationwide and
compulsory audit started in 2013 and registers all
patients, including patient and treatment character-
istics, with an aortic aneurysm and/or dissection un-
dergoing surgical treatment in the Netherlands. We
included all patients with a primary RAAA regis-
tered in the DSAA between January 2013 and
December 2017. All patients with a thoracic aortic
aneurysm/dissection, undefined aneurysm/dissec-
tion, and all patients with a secondary reinterven-
tion of a previous aortic aneurysm repair were
excluded.
Verification of the DSAA data was carried out in
2015 by a third trusted party, through a random
sample of hospitals.12,13
Primary Outcome
The primary outcome of this study was postopera-
tive mortality, which was defined as mortality
within 30 days after surgery or during admission
(30 days/in-hospital).
Statistical Analysis
Patients were divided in 2 groups, EVAR or OSR,
based on ‘‘start of treatment’’. Patient characteristics
and hospital-related factors were compared be-
tween the groups, using T-tests and chi-square tests.
Crude postoperative mortality rates between pa-
tients treated with EVAR and OSR were compared,
using a linear regression model. When considering
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a binary outcome, it is standard practice to use logis-
tic regression. The effect of EVAR versus OSR will
then be estimated as a (log) odds ratio. As we prefer
to estimate the effect as a risk difference (RD), we
used linear regression.
Subsequently, we used 3 different methods to
adjust for confounding when estimating the RD: a
linear model adjusted for confounders, a propensity
score (PS), that is the probability of getting a certain
treatment, adjusted for observed confounders, and
an IV analysis adjusted for observed and unobserved
confounders.
Adjusted linear regression analysis. To correct for
observed confounders, we used a linear regression
model to compare adjusted mortality rates between
patients treated with EVAR and OSR. Patient char-
acteristics based on V(p)-POSSUM variables, year
of surgery, and hospital volume of patients with
an RAAA, were entered as covariables in this
model.14,15
Propensity score analysis. The propensity score
analysis was carried out in 2 successive steps. In
the first Step, a multivariable logistic regression
analysis (ENTER model with a P-value at 0.05) for
the ‘‘choice of treatment’’ was performed. The
same patient and hospital characteristics as used in
the adjusted linear regression analysis were entered
as covariables in this model.
In the second step, an RD was estimated, using a
multivariable linear regression analysis for the pri-
mary outcome ‘‘postoperative mortality’’, adjusted
for the PS obtained in step 1 and the choice of treat-
ment as covariables.
Instrumental variable analysis. First, we divided all
hospitals in 2 groups with the median %EVAR per
hospital as a cutoff point: those with a low %
EVAR in patients with an RAAA (0e37% EVAR)
and those with a high %EVAR (38e100% EVAR).
We demonstrate the distribution of measured
possible confounders between these 2 groups.
An IV analysis can be used to estimate the effect
of a treatment in observational data, corrected for
unobserved confounders. The IV is a factor that
highly influences the choice of treatment but has
no independent influence on patient outcome.
The IV is thus not related to the prognosis of the pa-
tient. An IV analysis behaves as a pseudorandomiza-
tion, in which patients are weighed based on the
probability of getting a certain treatment. When us-
ing an IV analysis, one does not compare individual
patients with different treatments, but one com-
pares the outcomes of patients with a different
chance of getting a certain treatment. The methods
of IV analysis have also been described in detail
elsewhere.11
When using an IV analysis to compare postoper-
ative mortality after OSR and EVAR in patients with
an RAAA, we had to make 2 assumptions:
1. There is no association between patient charac-
teristics and the hospital where patients are
treated. In the Netherlands, patients with an
RAAA are admitted to nearest hospital perform-
ing acute AAA surgery.
2. As the Netherlands has a homogeneous care
landscape with an overall high quality standard,
quality of care is comparable between hospitals
performing acute AAA surgery.
Based on these assumptions the following anal-
ysis was performed. The percentage of patients
with an RAAA treated with EVAR per hospital (%
EVAR) (i.e. treatment preference of the hospital)
was chosen as the IV. The strength of the IV was
tested with a partial F-statistic. Subsequently, the
IV analysis was performed with a two-Stage least
square model. The covariables used in this model
were the same as in the first step of the PS analysis.
Outcome was reported in an RD between EVAR and
OSR. Finally, the IV model itself was tested with a
‘‘test for weak instruments’’ and a ‘‘Wu-Hausman
test’’.
All statistical analyses were performed using R
statistical software (version 3.4.0). When data
were missing for continues variables used in the
regression analyses, the mean was imputed. Data
were most frequently missing for preoperative heart
rate (13%) and systolic blood pressure (9.0%).
RESULTS
Participants and Descriptive Analysis
We identified 2660 patients with an RAAA operated
between January 2013 and December 2017. All pa-
tients with a thoracic aneurysm (76, 2.8%), unde-
fined aneurysm (45, 1.7%), revision of a previous
aortic aneurysm repair (80, 3.0%), or incomplete
data (40, 1.5%) were excluded. A total of 2419 pa-
tients were included for analyses, of which 1489
(61.6%) were treated with OSR and 930 (38.4%)
with EVAR. Twenty-seven (1.1%) EVAR patients
were converted to OSR and remained in the EVAR
group for analysis. The EVAR group consisted of
86% men, compared with 84% of men in the OSR
group (P ¼ 0.075). Patients who underwent EVAR
were significantly older than patients who under-
went OSR (75.3 SD 8.8 versus 73.6 SD 7.8,
P < 0.001) and had significantly more often a
normal Glasgow Coma Scale (GCS) (72% vs. 63%,
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Table I. Patient characteristics per surgical treatment
Patient characteristics
EVAR OSR
Pn % n %
Number of patients 930 1489
Age (mean, years) 75.3 SD 8.8 73.6 SD 7.8 0.000
Sex 0.075
Male 802 86.2% 1244 83.5%
Female 128 13.8% 245 16.5%
Year of surgery 0.000
2013 122 13.1% 301 13.1%
2014 198 21.3% 325 21.3%
2015 192 20.6% 321 20.6%
2016 205 22.0% 293 22.0%
2017 213 22.9% 249 16.7%
Cardiac state 0.039
No abnormalities 385 41.4% 659 44.3%
Peripheral edema, cardiomegaly 68 7.3% 82 5.5%
Raised CVP, use of coumarin,
borderline cardiomyopathy
15 1.5% 18 1.2%
Medication for hypertension, angina
pectoris, diuretics, or digoxin
324 34.8% 465 31.2%
Unknown 138 14.8% 265 17.8%
Pulmonary state 0.002
No dyspnea 580 62.4% 904 60.7%
Dyspnea 141 15.2% 205 13.8%
Severe dyspnea 48 5.2% 45 3.0%
Unknown 161 17.3% 335 22.5%
Malignancy 0.002
None 816 87.7% 1367 91.8%
Current 40 4.3% 33 2.2%
History of malignancy 74 8.0% 89 6.0%
Last preoperative ECG 0.001
No abnormalities 274 29.5% 421 28.3%
Atrial fibrillation 59 6.3% 68 4.6%
Ischemia 33 3.5% 43 2.9%
Other abnormalities 222 23.9% 292 19.6%
Unknown/no ECG performed 342 36.8% 665 44.7%
Diameter (mean, mm) 76 SD 16.0 80 SD 16.6 0.000
Hart rate (mean, BPM) 87 SD 21 87 SD 22 0.852
Systolic blood pressure (mean, mm Hg) 112 SD 33 109 SD 34 0.007
Glasgow Coma Scale 0.000
GCS 15 673 72.4% 931 62.5%
GCS 12e14 127 14% 206 13.8%
GCS 9e11 24 2.6% 56 3.8%
GCS <9 26 2.6% 114 7.7%
Unknown 80 9.3% 182 12.2%
Preoperative laboratory results
Hemoglobin (mmol/L) 7.2 SD 1.4 7.3 SD 1.4 0.613
Leukocytes (109/L) 14.2 SD 5.5 13.6 SD 5.4 0.013
Creatinine (mmol/L) 112 IQR 91e133 111 IQR 88e131.5 0.195
Sodium 0.077
Normal sodium 725 78.0% 1205 80.9%
Hyponatremia/hypernatremia 205 22.0% 284 19.1%
Potassium 0.493
Normal potassium 763 82.0% 1205 80.9%
Hypopotassemia/hyperpotassemia 167 18.0% 284 19.1%
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P < 0.001). Other differences in comorbidity and
clinical presentation are displayed in Table I. Over
the years 2013e2017 there was an increase in the
EVAR use from 29% to 46%.
Outcome Data and Main Results
The unadjusted postoperative mortality after OSR
was 34.9% (n ¼ 519) and 22.6% (n ¼ 210) after
EVAR. Using an unadjusted linear regression, the
RD in postoperative mortality after OSR and EVAR
was 12.3%, with a 95% confidence interval (CI) of
8.5e16%.
Case mixeadjusted linear regression analysis. The
mortality difference, adjusted for measured con-
founders was 12.3% (95%CI 9.6e16.7%), in favor
of patients with an RAAA treated with EVAR
(Table II.).
Propensity score analysis. Step 1: Patient character-
istics of patients with an RAAA associated with
receiving EVAR were increased age (odds ratio
(OR) 1.03, 95% CI 1.02e1.04), leukocytes between
10.0 109/Le14.9 109/L (OR 1.26, 95%CI 1.00e
1.59) or more than 20  109/L (OR 1.55, 95% CI
1.23e2.14), and current malignancy (OR 1.67,
95%CI 1.02e2.74) (Table III.). Patients with female
gender (OR 0.64, 95% CI 0.49e0.83), GCS of 9e11
(OR 0.59, 95% CI 0.35e0.98), GCS <9 (OR 0.34,
95% CI 0.21e0.54) or an unknown GCS (OR 0.67,
95% CI 0.50e0.91), increased aneurysm diameter
(OR 0.99, 95% CI 0.98e0.99), systolic blood pres-
sure of <80 mm Hg (OR 0.73, 95% CI 0.55e0.96),
and/or unknown pulmonary status (OR 0.75, 95%
CI 0.59e0.97) were less likely to receive EVAR. In
addition, patients operated in hospitals with a
higher volume and patients operated in later years
of the study were significantly more likely to receive
EVAR.
Step 2: In patients with an RAAA, the RD,
adjusted for the probability of treatment with
EVAR (PS for EVAR calculated in step 1), was
13.2% (95% CI 9.3e17.1%) in favor of treatment
with EVAR (Table IV).
Instrumental variable analysis. The percentage of
treatment with EVAR in patients with an RAAA
ranged from 0% to 100% (median: 37% EVAR) be-
tween 61 hospitals. 1220 patients were operated in
hospitals with a low %EVAR and 1199 patients in
hospitals with a high %EVAR. The mean %EVAR
in hospitals with a low %EVAR was 25.2% (0e
37%) compared with a mean of 52.0% (38e
100%) in hospitals with a high %EVAR in patients
with a RAAA (P < 0.001).
Table V shows the distribution of observed
possible confounders between the 2 groups of
hospitals. The crude mortality in hospitals with a
low %EVAR was 31.1% (380 of 1220) vs. 29.1%
(349 of 1199) in hospitals with a high %EVAR, RD
2.0% (95% CI 1.6 to 5.7%).
To adjust also for unobserved confounders, we
used the%EVAR per hospital as an IV (partial F-sta-
tistic >10). The estimated RD in patients with an
RAAA treated with EVAR, using an IV analysis
(2SLS model), was 8.9% (95% CI 1.1 to 18.9%)
compared with patients with an RAAA treated
with OSR.
Finally, the test for weak instrument was not
rejected, which suggests that the%EVAR per hospi-
tal is not a weak instrument. The Wu-Hausman test
was rejected, from which we can conclude that the
IV analysis can be used additional to a standard
linear regression.
DISCUSSION
Between 2013 and 2017, 2419 patients underwent
RAAA surgery in the Netherlands, of which 62%
was treated with OSR and 38%with EVAR. Patients
were treated in 61 hospitals, and percentage of treat-
ment with EVAR varied from 0% to 100%. The
crude postoperative mortality after OSR was
34.9% and 22.6% after EVAR. With standard linear
regression analysis and PS analysis adjusting for
observed confounders, a significant 30 days/in-hos-
pital survival benefit of 12.3% and 13.2%, respec-
tively, could been demonstrated for patients with
an RAAA undergoing EVAR, compared with pa-
tients with an RAAA undergoing OSR. Using IV
analysis (pseudorandomization) to adjust for
observed and unobserved confounders, a postoper-
ative survival benefit of approximately 8.9% was
seen in EVAR patients. In addition, patients oper-
ated in hospitals with a high %EVAR in patients
with an RAAA had a 2.0% lower crude postopera-
tive mortality than patients operated in hospitals
with a low %EVAR in patients with an RAAA.
The landmark trials evaluating treatment strate-
gies in patients with an RAAA could not show a sig-
nificant survival benefit after treatment with EVAR
compared with OSR.2e5 Respectively, for the AJAX,
ECAR, and IMPROVE trial, mortality differences of
4.0% (OSR 25% versus EVAR 21%, P ¼ 0.66),
6.0% (OSR 25% vs. EVAR 18%, P ¼ ns), and
2.0% (OSR 37.4% vs. EVAR 35.4%, P ¼ 0.62)
were found. The inclusion of patients and randomi-
zation methods turned out to be obstacles in these
trials. The AJAX and ECAR trial only included pa-
tients with an RAAA suitable for both surgical tech-
niques, which led to the exclusion of, respectively,
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Table II. Linear regression analysis for postoperative mortality in patients with an RAAA
Patient characteristics Estimate SE P-value
Procedure
OSR
EVAR 0.131 0.018 <0.001
Gender
Male
Female 0.025 0.025 0.313
Age
Age 0.010 0.001 <0.001
Glasgow Coma Scale
GCS 15
GCS 12e14 0.089 0.026 0.001
GCS 9e11 0.232 0.049 <0.001
GCS <9 0.190 0.038 <0.001
GCS unknown 0.168 0.029 <0.001
Year of surgery
2013
2014 0.068 0.028 0.013
2015 0.000 0.028 0.990
2016 0.010 0.028 0.724
2017 0.042 0.029 0.148
Volume of ruptured patients
in hospital of treatment
<25
25e40 0.005 0.036 0.881
40e55 0.016 0.027 0.546
55e70 0.021 0.031 0.477
>70 0.975 0.001 0.014
Aneurysm diameter




>140 0.035 0.025 0.156
80e109 0.025 0.022 0.258
<80 0.078 0.027 0.004
Preoperative heart rate
70e79
80e99 0.010 0.027 0.713
>100 0.013 0.029 0.655
<70 0.016 0.030 0.596
Creatinine
<90
90e109 0.007 0.025 0.790
110e139 0.083 0.024 0.001
>140 0.101 0.028 <0.001
Hemoglobin
>8.50
7.5e8.49 0.038 0.026 0.148
6.0e7.49 0.022 0.025 0.386
<6 0.026 0.031 0.404
Leukocytes
<10.0
10.0e14.9 0.001 0.022 0.978
15.0e19.9 0.024 0.027 0.375
>20.0 0.014 0.032 0.673
(Continued)
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61% and 80% of all presented patients with an
RAAA.2e5 In addition, the inclusion seemed to be
rather conservative. The IMPROVE trial, on the
other hand, included all patients with an RAAA
and randomized patients by treatment strategy,
which led to many crossovers especially from the
EVAR to OSR group.3
Some observational studies, using standard statis-
tical methods, comparing mortality between both
techniques in patients with an RAAA, demonstrated
significant survival benefits after treatment EVAR,
varying from 6% to 33%.7e9,16,17 These results are
in line with the 12.3%-adjustedmortality difference
in our study. However, other observational studies
did not establish a significant mortality difference
between OSR and EVAR.18e20 The results of obser-
vational studies can be biased due to missing or
incomplete adjustment for confounding. PS
methods are previously used to control for the selec-
tion bias in patients with an RAAA, which
confirmed a postoperative survival benefit for pa-
tients with an RAAA treated with EVAR.21,22 Gun-
narsson et al. suggested that besides differences in
baseline characteristics, the primary treatment strat-
egy of a hospital in patients with an RAAA could in-
fluence the results of the comparison between
EVAR and OSR.23 However, they found no associa-
tion between outcome and EVAR preference, but
Table II. Continued
Patient characteristics Estimate SE P-value
Sodium
Normal sodium
Hyponatremia 0.023 0.022 0.301
Hypernatremia 0.231 0.071 0.001
Potassium
Normal potassium
Hypokalemia 0.019 0.027 0.489
Hyperkalemia 0.027 0.034 0.418
Malignancy
None










>2 mm at rest)
0.209 0.051 <0.001


















Unknown 0.081 0.027 0.003
Pulmonary status
No dyspnea
Dyspnea 0.050 0.026 0.038
Severe dyspnea 0.198 0.046 <0.001
Unknown 0.061 0.024 0.013
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they only used conventional logistic regression
analysis adjusting for observed confounders.
IV methods have long been used in economic
studies and are being increasingly used in health
studies.11 In studies of various medical specialties,
this technique has been used to control for unob-
served confounders, such as treatment preference
of a physician, when comparing treatments.10,24e
27 IV analysis is particularly useful when large differ-
ences in treatment strategy exists. This applies for
instance to RAAA care in the Netherlands, where
the percentage of treatment with EVAR varied
from 0% to 100% between hospitals.
With the use of IV analysis in patients with an
RAAA undergoing surgical treatment in the
Netherlands, a survival benefit of 8.9% in patients
Table III. Propensity score for treatment with
EVAR
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GCS 9e11 0.59 0.35e0.98
GCS <9 0.34 0.21e0.54
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1.23 0.74e2.05






















Severe dyspnea 1.51 0.96e2.37
Unknown 0.75 0.59e0.97
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who underwent EVAR compared with patients who
underwent OSR was established. However, the CIs
were wide (1.1e18.9%) resulting in a nonsignifi-
cant RD. Wide CIs are inherent to IV analysis, as it
compares the outcome of patients with a different
chance of getting a certain treatment, instead of
comparing the outcome of individual patients. In
our study, we used the %EVAR per hospital as the
IV, by which data were aggregated on the level of
the 61 RAAA hospitals in the Netherlands and
therefore resulted in an RD with broad CIs. IV ana-
lyses are particularly useful in larger cohorts, in
which more patients with a different chance of
receiving a certain treatment (i.e. hospitals) can be
identified. International collaboration and the
merging of national data sets might be useful for
repeating this analysis and could possibly result in
a more precise estimation.
The mortality difference resulting from our IV
analysis represents the difference in mortality be-
tween the situation when all patients were treated
with EVAR compared with the situation where all
patients were treated with OSR. The daily practice
is obviously more differentiated, as not all RAAAs
are anatomically suitable for treatment with EVAR.
The currentmean treatment ratio in patientswith
an RAAA in the Dutch population is 37% EVAR
versus 63% OSR. The EVAR percentage is relatively
high compared with Denmark (8.2%) and Norway
(21%), and more comparable to Sweden (30%)
and the United Kingdom (41%).28,29 Moreover,
the VASCUNET collaboration reported that 23% of
patients with an RAAA was treated with EVAR in
the 11 participating countries between 2010e
2013.30 Over time, the percentage of EVAR
increased from 29% in 2013 to 46% in 2017. These
numbers give the impression that experience with
EVAR in RAAAs and adaptation of the care system
to be able to use EVAR in an acute setting could
play a role in the choice for EVAR in these patients.
As OSR is less and less performed in the elective
setting, there are concerns that experience with
the OSR declines. The survival benefit we found in
patients with an RAAA treated with EVAR could
therefore also be the result of the loss of experience
with OSR. However, when comparing mortality
rates of OSR in patients with an RAAA of the
DSAA, SWEDVASC, and the Cochrane review of
the trials, respectively, 30%, 34%, and 37%, the
outcome of OSR did not decline over time.6,23More-
over, the lower mortality of EVAR in the DSAA
(22%) and SWEDVASC (22%) than the trials
(34%) indicates a possible improvement of EVAR
results in patients with an RAAA. One can speculate
that the trials came to early, where the EVAR tech-
nique for RAAA was still in development.
When comparing surgical procedures, it is also
important to evaluate long-term survival. A meta-
analysis of the 3 randomized trials showed a nonsig-
nificant trend to lowermortality in patients who un-
derwent EVAR after 1-year follow-up.31 In addition,
the IMPROVE trial investigators reported a lower
overall mortality in EVAR patients at 3-year
follow-up (EVAR 48% versus OSR 56%, hazard ra-
tio 0.92, 95%CI 0.75e1.13) and a comparable over-
all mortality of approximately 60% at 7-years
follow-up.32 Unfortunately, the DSAA cannot pro-
vide information on long-term survival. In the
future, this may be possible through a link with
other population databases.
As the DSAA only registers patients who received
surgical intervention, it does not provide informa-
tion on the number of patients presented with an
RAAA who were denied for surgery or died before
surgical intervention could take place. When evalu-
ating the outcomes of RAAA care, it would be useful
to have this information, as the decision for surgical
intervention can differ between hospitals and might
be associated with EVAR preference, or not. Hospi-
tals could potentially influence their outcomes by
selecting patients for surgical treatment.
To use an IV analysis, 2 assumptions were made.
When comparing 2 pharmaceutical treatments, you
can safely state that the quality of the treatment is
equal in all hospitals. When comparing surgical
treatments, this is more uncertain, as surgeon’s
Table IV. Comparison of mortality in the patient treated with OSR and EVAR, corrected for the
propensity score
Treatment Beta Lower 95% CI Upper 95% CI
Surgical procedure
OSR Ref.
EVAR 0.13 0.17 0.09
Propensity score for treatment with EVAR 0.11 0.03 0.24
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Table V. Distribution of measured confounders between hospitals with a low and high percentage of
treatment with EVAR, divided by the median of 37% as cutoff point
Patient characteristics
Hospitals with low %
EVAR (0e37%)
Hospitals with high %
EVAR (38e100%)
Pn ¼ 1220 % n ¼ 1199 %
Surgical procedure 0.000
OSR 913 74.8% 576 48%
EVAR 307 25.2% 623 52%
Year of surgery 0.143
2013 218 17.9% 205 17.1%
2014 259 21.2% 264 22.0%
2015 277 22.7% 236 19.7%
2016 254 20.8% 244 20.4%
2017 212 17.4% 250 20.9%
Volume of ruptured patients in hospital of
treatment
0.000
<25 192 15.7% 147 12.3%
25e40 124 10.2% 100 8.3%
40e55 518 42.5% 426 35.5%
55e70 124 10.2% 301 25.1%
>70 262 21.5% 225 18.8%
Gender 0.375
Male 1024 83.9% 1022 85.2%
Female 196 16.1% 177 14.8%
Age 0.466
Age 74.1 SD 7.9 74.4 SD 8.6
Pulmonary status 0.140
No dyspnea 743 60.9% 741 61.8%
Dyspnea 168 13.8% 178 14.8%
Severe dyspnea 40 3.3% 53 4.4%
Unknown 269 22.0% 227 18.9%
Cardiac status 0.001
None 520 42.6% 524 43.7%
Peripheral edema, cardiomegaly 62 5.1% 88 7.3%
Raised CVP, use of coumarin,
borderline cardiomyopathy
16 1.3% 17 1.4%
Medication for hypertension, angina
pectoris, diuretics, or digoxin
384 31.5% 405 33.8%
Unknown 238 19.5% 165 13.8%
Preoperative ECG 0.000
No abnormalities 341 28.0% 354 29.5%
Atrial fibrillation (60e90 bpm) 58 4.8% 69 5.8%
Ischemia (ST depression >2 mm at rest) 34 2.8% 42 3.5%
Other abnormalities 224 18.4% 290 24.2%
No preoperative ECG performed 563 46.1% 444 37.0%
Malignancy 0.477
None 1108 90.8% 1075 89.7%
Current malignancy 32 2.6% 41 3.4%
History of malignancy, curatively
treated
80 6.6% 83 6.9%
Aneurysm diameter (mm) 0.253
Diameter 78,7 SD 16,3 78,0 SD 16,4
Glasgow Coma Scale 0.157
GCS 15 789 65.4% 806 67.2%
GCS 12e14 158 13.0% 175 14.6%
GCS 9e11 39 3.2% 41 3.4%
(Continued)
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skills affects the quality of the treatment. The broad
CIs around the RD, which are previously mentioned
and inherent to the use of IV methods, are another
limitation. Randomization remains the golden stan-
dard but has other obstacles in comparing results in
patients with an RAAA. Therefore, the IV method
can be a good alternative for this research question,
as it tries to find a randomized experiment
embedded in an observational study.
Our findings suggest that an EVAR-first strategy
in patients with an RAAA may improve postopera-
tive survival. An EVAR teammust then be available
24/7. This has substantial implications for the orga-
nization of RAAA care. Currently, there are 61
hospitals in the Netherlands that perform RAAA
surgery and improvement of care necessitates
further concentration of RAAA care. A new volume
standard of at least 40 interventions (elective and/or
acute) yearly is set by our National Healthcare Insti-
tute and Inspectorate of Healthcare, which will
contribute to concentration of RAAA care with 24/
7 availability of an EVAR team.
CONCLUSION
Using standard statistical methods, the postopera-
tive 30-day/in-hospital survival of patients with
an RAAA undergoing EVAR was approximately
Table V. Continued
Patient characteristics
Hospitals with low %
EVAR (0e37%)
Hospitals with high %
EVAR (38e100%)
Pn ¼ 1220 % n ¼ 1199 %
GCS <9 80 6.6% 60 5.0%
GCS unknown 145 11.9% 117 9.8%
Preoperative systolic blood pressure (mm
Hg)
0.253
110e139 396 32.5% 387 32.3%
>140 260 21.3% 225 18.8%
385 31.6% 383 31.9%
<80 179 14.7% 204 17.0%
Preoperative heart rate (BPM) 0.751
70e79 158 13.0% 165 13.8%
80e99 498 40.8% 466 38.9%
100 327 26.8% 336 28.0%
<70 327 19.4% 232 19.3%
Hemoglobin (mmol/L) 0.541
>8.50 240 19.7% 215 17.9%
7.5e8.49 310 25.4% 328 27.4%
6.0e7.49 469 38.4% 450 37.5%
<6 201 16.5% 206 17.2%
Leukocytes (109/L) 0.955
<10.0 273 22.4% 259 21.6%
10.0e14.9 561 46.0% 558 46.5%
15.0e19.9 254 20.8% 247 20.6%
>20.0 132 10.8% 135 11.3%
Creatinine (mmol/L) 0.359
<90 306 25.1% 305 25.4%
90e109 280 23.0% 256 21.4%
110e139 401 32.9% 377 31.4%
>140 233 19.1% 261 21.8%
Sodium 0.894
Normal sodium 969 79.4% 961 80.2%
Low sodium 233 19.1% 220 18.3%
High sodium 18 1.5% 18 1.5%
Potassium 0.347
Normal potassium 983 80.6% 985 82.2%
Low potassium 150 12.3% 125 10.4%
High potassium 87 7.1% 89 7.4%
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12% lower than in those undergoing OSR in a
large consecutive series of unselected patients in
the DSAA. In addition, an IV analysis showed a
clinical relevant mortality difference in favor of pa-
tients who underwent EVAR. By taking both re-
sults into account, it is plausible to think that a
strategy with a preference for EVAR in patients
with an RAAA will result in a decreased postoper-
ative mortality.
The authors would like to thank all surgeons, registrars,
physician assistants, and administrative nurses who registered
all patients in the DSAA and in the Dutch Surgical Aneurysm
Audit group.
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